Navigation Links
NeurogesX Reports Second Quarter 2008 Results
Date:8/13/2008

Second Quarter 2008 Corporate Highlights: - European marketing application under review for NGX-4010 in peripheral

neuropathic pain - NGX-4010 NDA for PHN on track for submission in second half of 2008

- IND submitted and opened for NGX-1998 liquid capsaicin formulation

- Phase 1 clinical trial of NGX-1998 initiated - Journal Neurology published positive Phase 3 data on NGX-4010 in HIV-DSP

SAN MATEO, Calif., Aug. 13 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for the quarter ended June 30, 2008.

In the second quarter of 2008, the Company continued on its path toward potential commercialization of its lead product candidate, NGX-4010, a dermal capsaicin patch designed for the treatment of certain neuropathic pain conditions. On the U.S. regulatory front, the Company has been preparing a New Drug Application (NDA) to support marketing approval of NGX-4010 for the treatment of post-herpetic neuralgia (PHN), and is on track to submit an NDA to the U.S. Food and Drug Administration (FDA) later this year.

The Company continues to pursue the European approval of its Marketing Authorization Application (MAA) for NGX-4010 in neuropathic pain, which the European Medicines Agency (EMEA) accepted for review in September 2007. In September of 2008, the Company, with the EMEA's agreement, plans to submit responses to the regulatory agency's Day 120 questions, which are part of the review process for the MAA.

In addition to focusing on regulatory activities for NGX-4010, NeurogesX has made significant progress with
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NeurogesX to Report Second Quarter 2008 Financial Results
2. NeurogesX Opens Investigational New Drug Application for Capsaicin Liquid Formulation NGX-1998
3. NeurogesX to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
4. NeurogesX Reports First Quarter 2008 Results
5. NeurogesX to Report First Quarter 2008 Financial Results
6. NeurogesX to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference
7. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
8. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX Closes $25 Million Private Placement
11. NeurogesX, Inc. Announces $25 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company focused on the development ... poster presentation at the International Society for Cellular ... chronic Achilles tendinosis currently in a Phase 1/2 ... 29 th from 5:30 PM to 7:00 ...
(Date:5/20/2015)... SOUTH SAN FRANCISCO, Calif. , May 20, ... VCYT ) today presented preliminary data demonstrating ... help distinguish idiopathic pulmonary fibrosis (IPF) from other ... bronchoscopy. The findings suggest the classifier,s potential to ... expensive surgery to resolve ambiguity in IPF diagnosis ...
(Date:5/20/2015)... , May 19, 2015 Research and Markets ... of the "Global Cell Therapy Market Outlook 2020 ... of cell therapy in tissue and regenerative medicine is ... no other options which could help in the growth ... this segment but they are unable to form new ...
(Date:5/20/2015)... 2015  Health eCareers, the healthcare industry,s online ... job seekers looking for the flexibility of short-term ... and online tool dedicated exclusively to temporary and ... SHIFT enables employers to quickly find and hire ... diem and other temporary positions, eliminating the time ...
Breaking Biology Technology:RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3
... 27 Following the successful acquisition of,Drug Development ... organization, announced today that it has fully,integrated its ... branded as,Chiltern Early Phase., Chiltern Early Phase ... pharmaceutical industry via its two well established units ...
... 26 Based on its recent analysis,of the ... presents Kionix, Inc. with the 2008 Global Frost ... a leadership position,in analog output accelerometer products, and ... KXSC7 accelerometer release, a natural extension of,its product ...
... Industries is,pleased to announce the addition of long ... newest member on their Board of Directors., ... Mr.,Skiven oversaw during his 15 years as Executive ... logical that he would join the board of ...
Cached Biology Technology:Chiltern Early Phase: Fully Integrated and Business Ready 2Frost & Sullivan Recognizes Kionix's Dominance in the MEMS Accelerometers Market Through Product Line Strategy 2Frost & Sullivan Recognizes Kionix's Dominance in the MEMS Accelerometers Market Through Product Line Strategy 3Frost & Sullivan Recognizes Kionix's Dominance in the MEMS Accelerometers Market Through Product Line Strategy 4GM Exec Joins Bio-Reaction Industries' Board of Directors 2
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... A 23andMe study of consumers, reactions to genetic testing ... in individuals, those individuals had few negative reactions to ... results prompted people to take positive steps, including follow-up ... who could also be at risk. The study, ...
... researchers "cured" a strain of bacteria of its ability ... implications for a long-standing public health crisis. ... to remove the ability of the Pseudomonas aeruginosa microorganism ... access to food and oxygen. Over 120 ...
... researcher has identified characteristics in benign breast disease ... Michele Cote, Ph.D., associate professor of oncology ... Ann Karmanos Cancer Institute, recently reviewed data from ... underwent breast biopsies between 1997 and 2000. Researchers ...
Cached Biology News:Consumers have few negative reactions to the results of genetic testing for cancer mutations 2Lack of energy an enemy to antibiotic-resistant microbes 2Lack of energy an enemy to antibiotic-resistant microbes 3Cancer risk for African-American women with benign breast disease factors Wayne State finds 2
...
sTNF-receptor I Polyclonal Antibody 100 ug affinity purified rabbit anti-human sTNF-receptor I polyclonal antibody. Performs well in WB/Elisa/Neutralization....
...
Smac/DIABLO (CT) - IgG for Western Blotting, Host: Rabbit Family: Smac/DIABLO...
Biology Products: